Abstract
Introduction

40
Lipocalin 2 (Lcn2, also known as neutrophil gelatinase-associated lipocalin (NGAL)) is involved in 41 several physiological processes including inflammation, iron metabolism, cell death and cell survival. 42
Increased Lcn2 levels were found in the central nervous system (CNS) of patients with 43 neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease. Moreover, 44 mechanistic studies showed that Lcn2 may contribute to their pathophysiology (Kim et effects (Belaidi and Bush, 2016) , maybe partly via reducing the brain iron accumulation that 54 characterizes many CNS conditions. Interestingly, deferoxamine was found to decrease Lcn2 levels in 55 certain animal models of CNS injury (Dong et al., 2013; Zhao et al., 2016) . However, it is still unknown 56 if iron chelators may reduce Lcn2 production in the context of AD. 57
58
The aim of this study was to explore (1) whether the iron chelators deferoxamine and deferiprone 59 are able to inhibit Aβ 1-42 -induced Lcn2 production in cultured astrocytes, and (2) whether Aβ may 60 affect astrocytic iron metabolism, and the potential effect of Lcn2 hereon by comparing Aβ-treated 61 wild-type (WT) and Lcn2 knock-out (Lcn2 KO) astrocytes. 
Results
82
Firstly, it was confirmed that Aβ 1-42 induced Lcn2 production and secretion by astrocytes ( Fig. 1a-b) . 83 Intracellular Lcn2 levels peaked 36h after Aβ 1-42 treatment (p < 0.0001). This corresponds to kinetics 84 of Lcn2-induction upon TNF-α, IL-1β and LPS-stimulation ((Naudé et al., 2012) and Suppl. Fig. 1a-b) . 85
Secondly, deferoxamine significantly reduced Aβ-induced Lcn2 production, after 36h co-incubation (p 86 < 0.0001, Fig. 1c-d) . The inhibitory effect of deferoxamine on Aβ-induced Lcn2 production was 87 confirmed with another iron chelator; deferiprone (Suppl. Fig. 1c-d) . indicating an increase in astrocytic iron accumulation upon Aβ exposure, independent of endogenous 96
Lcn2 production. Although increased astrocytic iron levels might be an important co-factor in the 97 induction of Lcn2, it appeared that iron alone is not sufficient to induce Lcn2 upregulation (Suppl. Fig.  98 1e). 99 100
Discussion
101
Results from this study suggest that iron chelators are potent inhibitors of Aβ-induced Lcn2 102 production in astrocytes, which may contribute to their reported neuroprotective effects. 103
Interestingly, it was proposed that iron-loaded deferiprone (unlike deferoxamine) may bind to Lcn2, 104 after which the iron-deferiprone-Lcn2 complex is excreted from the body (Zughaier et al., 2014) . 105
Certain iron chelators, i.e. deferiprone, might thus not only affect Lcn2 production but also its 106 removal from the body. 107
108
The modulation of Aβ-induced Lcn2 production by iron chelators further suggests that Aβ may act in 109 part via increasing iron levels in astrocytes (also illustrated in Fig. 1f ). This is supported by our result 110
showing that Aβ causes an increase in astrocytic ferritin levels. This is the first study to our best 111 knowledge that indicates iron accumulation in astrocytes upon direct Aβ-stimulation. This is in 112 accordance with the previously reported Aβ-induced iron accumulation in microglia ((McCarthy et al., 113 2018) and Suppl. Fig. 1f ) and a neuronal cell line (Wan et al., 2011) . Future experiments are required 114 to confirm the finding in astrocytes, including direct read-outs of iron accumulation. Moreover, 115 further investigations are needed to elucidate the role of disturbed iron metabolism in Aβ-induced6 astrocyte activation and Lcn2 production. Namely, while the current results may suggest a potential 117 involvement of disturbed iron metabolism in Aβ-induced Lcn2 production, it is possible that iron is 118 not essential, and that other factors and pathways are also involved. In addition, more work is 119 required to determine whether deferoxamine and deferiprone inhibit Aβ-induced Lcn2 production by 120 chelating iron, or also via alternative pathways. For example, it is known that deferoxamine and 121 deferiprone are not entirely specific for iron but are also able to chelate copper, suggesting that their 122 effects might partly rely on chelation of copper. Interestingly, we found that Aβ-induced Lcn2 123 production can be modulated by certain copper chelators: while bathocuproine disulfonic acid (a 124 membrane impermeable copper chelator) did not affect Lcn2 protein levels, tetrathiomolybdate (a 125 membrane permeable copper chelator) was shown to significantly reduce intracellular Lcn2 levels 126 (Suppl. Fig. 1g-j) . The observed inhibitory effect of tetrathiomolybdate on Lcn2 production may be 127 
